本季度信息
上海医药公布2026年中期报告，报告期内，公司实现营业收入1474.70亿元，同比增长4.15%。经调整后净利润28.28亿元，同比增长1.65%。同期经营活动现金流净流入44.50亿元，同比大幅增长349.78%。
从成本结构看，销售费用达65.38亿元，同比增长6.05%；管理费用27.40亿元，同比增长2.90%；研发费用9.71亿元，同比增长1.24%。报告期内，公司研发投入总额10.53亿元，占其医药工业销售收入的7.98%。
业务分项
医药工业方面，销售收入131.86亿元，同比增长8.44%。医药商业（分销）实现销售收入1342.83亿元，同比增长3.75%，合计带动公司整体营收稳健增长。
高管解读
上海医药管理层在报告中透露，本集团在坚持创新转型的基础上，将持续优化产品结构、强化市场推广和费用控制。下半年公司将“坚持‘强基提质增效能，创新攻坚促转型’的总体方针，紧扣‘十五五’开局要求，稳步推进既定经营目标与重点任务，持续夯实工业与商业两大板块的核心竞争力，提升运营效率及核心盈利能力，为公司高质量发展奠定更坚实基础。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.